Skip to main content
. Author manuscript; available in PMC: 2020 Sep 20.
Published in final edited form as: Curr Cancer Drug Targets. 2020;20(4):253–270. doi: 10.2174/1568009619666191202101330

Fig. 4.

Fig. 4.

Purine-based Hsp90 inhibitors – A) PU-3 was the first fully synthetic Hsp90 inhibitor and first of the purine-based class. B) BIIB021 and BIIB028 modify the N-7 and N-9 positions of the purine base. C-E) PU-H71, MPC-3100, Debio0932 each add a unique 1,3-benzodioxole moiety to the N-8 position via a thioether bond and a variable substituent to the N-9 position.